多基因风险评分预测eGFR:以碘海醇清除率验证
在RENIS队列1492名无心血管病、肾病或糖尿病的普通人群中,比较3种针对肌酐eGFR的多基因风险评分(PGS)对实测GFR(mGFR)和3种eGFR的预测性能。PGS对eGFRcr预测最佳(P<0.05),但在RENIS中估计的SNV效应量,9项比较中8项mGFR比eGFR大11%–46%(P<0.05);mGFR的窄义遗传力(0.47)高于eGFRcr(0.21)、eGFRcys(0.37)和eGFRcr-cys(0.42)。结论:对肌酐和胱抑素C有非GFR影响的SNV会影响GWAS结果,基于eGFR的GWAS应用更精确方法验证。
要点
- PGS对eGFRcr预测性能最佳,但对mGFR预测不同。
- SNV效应量在mGFR中比eGFR大11%–46%(8/9比较)。
- mGFR窄义遗传力0.47,高于eGFRcr、eGFRcys和eGFRcr-cys。
核心结论
- 对肌酐和胱抑素C有非GFR影响的SNV会影响GWAS结果。
- 基于eGFR的GWAS结果应使用实验性等更精确方法验证。
研究设计与样本
- 研究1492名来自挪威北部RENIS队列的普通人群,无既往心血管病、肾病或糖尿病。
- 测量碘海醇清除率,并使用富集GFR相关SNV的微阵列芯片进行基因分型。
- 比较3种已发表的针对肌酐eGFR的PGS对mGFR和3种eGFR的预测性能、窄义遗传力及SNV平均效应。
主要发现
- PGS对mGFR和3种eGFR的预测性能不同,对eGFRcr预测最佳(P<0.05)。
- 在RENIS队列中估计3种PGS的SNV beta系数,9项比较中8项mGFR的效应量比3种eGFR方法大11%至46%(P<0.05)。
- mGFR的窄义遗传力为0.47,高于eGFRcr的0.21、eGFRcys的0.37和eGFRcr-cys的0.42。
临床怎么用
- 解读基于eGFR的GWAS多基因风险评分时,需警惕肌酐和胱抑素C非GFR效应带来的偏倚。
- 在精准医学应用PGS预测肾功能时,优先考虑使用mGFR验证的评分。
局限性
- 研究基于挪威北部普通人群,结果外推需谨慎。
- 仅使用3种已发表的PGS,未涵盖所有eGFR相关SNV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Genome-wide association studies (GWAS) have identified hundreds of single nucleotide variants (SNVs) associated with estimated glomerular filtration rate (eGFR). eGFR has been used as a proxy phenotype because of the complexity and cost of measured GFR (mGFR) in large studies. Because eGFR is influenced by non-GFR factors, these GWAS results may be biased compared with a hypothetical study using mGFR. We aimed to investigate this by comparing aggregate measures of genetic effects on mGFR and eGFR. METHODS: We studied 1492 persons from the Renal Iohexol Clearance Survey (RENIS) cohort, a representative sample of the general population in Northern Norway without preexisting cardiovascular disease, kidney disease, or diabetes. We measured iohexol-clearance, and genotyping was performed with a microarray chip enriched for GFR-related SNVs. We compared the performance of 3 published polygenic risk scores (PGS) developed for creatinine-based eGFR (eGFRcr), narrow-sense heritability (h2) and the mean effect of SNVs on mGFR, eGFRcr, cystatin C-based eGFR (eGFRcys) and eGFRcr-cys. RESULTS: The performance of the PGS differed for mGFR and the 3 eGFRs, with best performance for prediction of eGFRcr (P < 0.05). However, when the beta coefficients of the SNVs in the 3 PGS were estimated in the RENIS-cohort, their magnitude was 11% to 46% greater for mGFR than for the 3 eGFR methods in 8 of 9 comparisons (P < 0.05). mGFR had higher h2 (0.47) than eGFRcr (0.21), eGFRcys (0.37), and eGFRcr-cys (0.42). CONCLUSIONS: SNVs with non-GFR effects on creatinine and cystatin-C influence GWAS results. The results of GWAS using eGFR should be validated using experimental and other more precise methods.
引用
- Eriksen BO, Kretzler M, Nair V, et al. Polygenic Risk Scores Predicting Estimated GFR Validated With Iohexol Clearance. Kidney Int Rep. 2025. PMID: 41541770. doi:10.1016/j.ekir.2025.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。